Dr. Joyce O'Shaughnessy, Dr. Anthony Lucci, & Dr. Mothaffar Rimawi - DB11 & DB05 Change HER2+ Care

Community Health Media · Jun 25, 2026 · 51m

The treatment landscape for early-stage HER2-positive breast cancer is evolving rapidly.

In this discussion, Dr. Joyce O'Shaughnessy, Dr. Anthony Lucci, and Dr. Mothaffar Rimawi explore how DESTINY-Breast11 (DB11) and DESTINY-Breast05 (DB05) are influencing treatment decisions in early HER2-positive breast cancer.

The conversation examines the growing role of neoadjuvant therapy, pathologic complete response (pCR), surgical de-escalation, residual disease management, and the integration of trastuzumab deruxtecan (T-DXd) into clinical practice.

Topics discussed include:

Why neoadjuvant therapy…